Every examination, imaging study and laboratory test included in each screening panel at Meinian Health Guangzhou — listed item by item, in plain language. Entry Panel $1,067 · Flagship Deep-Dive $1,997, both fixed USD prices.
This page expands the summaries on the main screening page into a complete item list. Each panel below is quoted by the center as its own complete list — the items shown are what each price covers, per the center's current published panel sheets. Where an item differs between men and women, it is marked. Minor item substitutions of equal clinical value may occur at the center's discretion; the written quotation for your booking is final.
The full one-day battery included in the Entry Panel. All laboratory tests below are fasting venous blood samples unless noted.
| Item | What it is |
|---|---|
| General examination | Height, weight, body-mass index and blood pressure — baseline metabolic and cardiovascular measurements. |
| Internal medicine examination | Physician auscultation and palpation of the chest, heart, lungs and abdomen — screens for heart rhythm irregularity, enlarged liver or spleen and abdominal masses. |
| Surgical examination | Palpation of superficial lymph nodes, thyroid, breast, spine, limbs and skin. |
| Digital rectal examination | Physician examination of the lower rectum — screens for hemorrhoids, rectal polyps and, in men, prostate enlargement. |
| ENT examination | Ear canals, eardrums, nasal passages, sinuses, throat and tonsils. |
| Dental examination | Lips, oral mucosa, gums, teeth, tongue and salivary glands — early detection of caries and gum disease. |
| Bone density screening | Quantitative ultrasound measurement at the heel — early detection of reduced bone mass and osteoporosis risk. |
| Resting electrocardiogram (ECG) | Records the heart's electrical activity — screens for arrhythmia and evidence of myocardial ischemia. |
| Item | What it is |
|---|---|
| General eye examination | Visual acuity, color vision, eyelids, conjunctiva, cornea and pupils. |
| Non-contact tonometry | Measures intraocular pressure without touching the eye — an important screening test for glaucoma. |
| Ophthalmoscopy | Direct examination of the retina and optic nerve — screens for macular degeneration and retinal vascular changes. |
| Slit-lamp examination | Microscopic examination of the cornea and lens — screens for cataract and corneal disease. |
| AI-assisted retinal fundus photography | A wide-field photograph of the retina analyzed by artificial-intelligence software — screens for diabetic retinopathy, hypertensive retinopathy, macular degeneration and signs of glaucoma. |
| Item | What it is |
|---|---|
| Transcranial Doppler (TCD) | Ultrasound of the blood flow in the brain's arteries — a safe, non-invasive assessment of cerebral blood supply. |
| Carotid ultrasound | Ultrasound of the neck arteries — measures plaque and stenosis, the standard screening test for carotid atherosclerosis. |
| Echocardiogram (with images) | Ultrasound of the heart in motion — evaluates chamber size, valve function and pumping strength. |
| Item | What it is |
|---|---|
| 1.5T brain MRI — plain scan | Magnetic resonance imaging of the brain (T1/T2/FLAIR/DWI sequences) — screens for infarcts, tumors, vascular lesions and other intracranial abnormalities. |
| 32-slice low-dose spiral chest CT | Low-radiation CT of the lungs — the established method for lung nodule screening. |
| Coronary artery calcium (CAC) scoring + AI lung nodule analysis | Performed on the same chest CT: quantifies calcified plaque in the coronary arteries (a marker of coronary atherosclerosis) and applies AI software to lung nodule detection. |
| Abdominal ultrasound | Liver, gallbladder, pancreas, spleen and kidneys — screens for fatty liver, stones, cysts and masses. |
| Thyroid ultrasound | Thyroid gland — screens for nodules, goiter and thyroid masses. |
| Urinary tract ultrasound | Kidneys, ureters and bladder — screens for stones, cysts and masses. |
| Prostate ultrasound (men) | Prostate size and morphology — screens for enlargement and calcification. |
| Breast ultrasound (women) | Both breasts — screens for lumps, cysts and masses. |
| Pelvic ultrasound (women) | Uterus and ovaries (transabdominal) — screens for fibroids, cysts and other pelvic abnormalities. |
| Item | What it is |
|---|---|
| Complete blood count with 5-part differential | 24 measured values covering red cells, white cells and platelets — screens for anemia, infection and blood disorders. |
| Liver function panel (11 analytes) | ALT, AST, gamma-GT, ALP, total/direct/indirect bilirubin, total protein, albumin, globulin and albumin/globulin ratio — screens for hepatitis, fatty liver and bile-duct disorders. |
| Lipid panel (4 items + ratio) | Total cholesterol, triglycerides, HDL-C, LDL-C and the TC/HDL ratio — standard cardiovascular risk assessment. |
| Small dense LDL cholesterol (sdLDL-C) | Measures the small, dense LDL particles that are more strongly associated with atherosclerotic cardiovascular risk than standard LDL. |
| Kidney function panel (3 items) | Urea, creatinine and uric acid — core markers of kidney function; uric acid also screens for gout. |
| Cystatin C | An independent marker of the kidney's filtration rate — detects early kidney function change, unaffected by age, diet or muscle mass. |
| Urine microalbumin (quantitative) | An early indicator of kidney and cardiovascular risk, particularly in diabetes and hypertension. |
| Fasting plasma glucose | The basic screening test for diabetes. |
| HbA1c (glycated hemoglobin) | Average blood glucose over the preceding 2–3 months — the standard diabetes screening and monitoring marker. |
| Adiponectin | A hormone marker associated with insulin resistance and type 2 diabetes risk. |
| Fasting insulin | Assesses pancreatic beta-cell activity and insulin resistance. |
| C-peptide | Assesses the pancreas's own insulin production — distinguishes type 1 from type 2 diabetes and is unaffected by injected insulin. |
| Homocysteine (Hcy) | An amino-acid marker used in cardiovascular risk assessment, particularly for coronary atherosclerosis. |
| Lipoprotein(a) — Lp(a) | A genetically determined lipid particle; elevated levels are associated with atherosclerotic cardiovascular disease. |
| High-sensitivity C-reactive protein (hs-CRP) | A vascular inflammation marker used in cardiovascular risk assessment. |
| Hemorheology panel | Whole-blood and plasma viscosity, erythrocyte sedimentation rate and hematocrit — measures blood flow characteristics. |
| Thyroid function panel (5 items) | FT3, FT4, TSH, anti-thyroglobulin antibody and anti-thyroid-peroxidase antibody — the standard panel for thyroid function and autoimmune thyroid disease. |
| Immune function panel | Complement C3 and C4, immunoglobulins IgG, IgA and IgM — supports assessment of inflammatory and immune conditions. |
| Total vitamin D | Measures vitamin D status — relevant to bone health and calcium metabolism. |
| Anemia panel (3 items) | Folate, vitamin B12 and ferritin — the standard workup for nutritional anemia. |
| Item | What it is |
|---|---|
| Urinalysis (dry-chemistry strip, with microscopy) | 15 measured values plus microscopic examination — screens for urinary-tract infection, kidney disease and diabetes-related changes. |
| Fecal occult blood test (take-home kit) | A self-administered stool test for hidden blood — a recognized screening method for colorectal disease; a positive result warrants colonoscopy follow-up. |
| Item | What it is |
|---|---|
| 13C urea breath test | A breath test for Helicobacter pylori infection — the bacterium associated with gastritis, peptic ulcer and gastric cancer risk. |
| Pepsinogen panel (PG I, PG II and PG I/II ratio) | Blood markers of stomach lining health — used in gastric-cancer risk stratification and screening for atrophic gastritis. |
| Item | What it is |
|---|---|
| AFP (alpha-fetoprotein) | The principal marker used in the monitoring of primary liver cancer. |
| CEA (carcinoembryonic antigen) | Used in the monitoring of colorectal, gastric, pancreatic, breast and lung malignancies. |
| CYFRA 21-1 | A marker with established value in non-small-cell lung cancer. |
| NSE (neuron-specific enolase) | Used in the workup and monitoring of small-cell lung cancer and neuroendocrine tumors. |
| CA 242 | Used in the monitoring of colorectal and pancreatic malignancies. |
| CA 125 | Used in the monitoring of ovarian, endometrial and other malignancies; also elevated in some benign conditions. |
| CA 19-9 | Used in the monitoring of pancreatic, biliary tract and gastrointestinal malignancies. |
| CA 15-3 | Used in the monitoring of breast cancer. |
| CA 72-4 | A gastrointestinal marker with particular application in gastric cancer screening. |
| Total and free PSA (men) | Prostate-specific antigen — the standard blood test in prostate cancer screening and monitoring. |
| SCC (squamous cell carcinoma antigen) | Used in the monitoring of squamous-cell malignancies of the lung, cervix, esophagus and skin. |
| Beta-hCG (men's panel) | Used in the workup of certain germ-cell tumors. |
| EBV VCA-IgA antibody | An Epstein-Barr virus antibody used in nasopharyngeal carcinoma screening — particularly relevant for populations from endemic regions. |
| Item | What it is |
|---|---|
| Gynecological examination | Physician examination of the female reproductive organs. |
| Vaginal discharge microscopy | Screening for vaginal and cervical infection. |
| ThinPrep cytologic test (TCT) | Liquid-based cervical cytology — the standard cervical cancer screening method. |
| HPV genotyping (25 types) | Tests for 17 high-risk and 8 low-risk HPV types — the standard cervical-cancer risk assessment alongside TCT. |
Women's items are included in the panel price. Guests who prefer not to have gynecological examination may decline those items on the day.
| Item | What it is |
|---|---|
| Venous blood collection | Single fasting draw covering the full laboratory panel. |
| Printed report | Full printed report with physician summary review. |
| Breakfast | Served after fasting blood work is complete. |
| Final physician review | A physician consolidates all findings into the summary report. |
The flagship panel covers the same core screening battery as the Entry Panel and adds the deep-dive studies below. The difference between the two panels concentrates in four areas: the stomach, the brain and neck vessels, continuous glucose, and advanced cardiac and kidney markers.
| The Flagship includes the same core physical examination, eye screening (AI fundus photography), cardiac and vascular ultrasound, ultrasound and imaging studies (brain MRI, chest LDCT with calcium scoring, abdominal and thyroid ultrasound), core laboratory panels, tumor markers, urine and stool tests, and service items listed in the Entry Panel above. |
| Item | What it is |
|---|---|
| Volumetric brain MRI protocol | A 3D thin-slice (1 mm) T1 acquisition on the same 1.5T platform, with software quantifying brain-region and hippocampal volumes against age norms — early screening for cognitive decline and brain atrophy, micro-infarcts and micro-bleeds. Includes: cognitive self-assessment questionnaire, AI brain-region analysis (100+ regions), and APOE genotype testing (electronic report) — a genetic marker used in Alzheimer's-disease and cardiovascular risk research. |
| Carotid plaque MRI | Dedicated vessel-wall MRI of the carotid arteries — images the arterial wall and plaque directly, beyond what standard ultrasound shows. Includes: stroke-risk self-assessment questionnaire, AI carotid plaque quantification, APOE genotype testing, and folate-metabolism genotype testing (electronic report) — a marker relevant to cardiovascular and hypertensive risk. |
The two packages run on the same 1.5T MRI platform on the same day; you choose one when booking. If you are unsure which suits you, we will advise at the initial case review.
| Item | What it is |
|---|---|
| Magnetically controlled capsule gastroscopy | A swallowable, magnetically steered capsule camera that images the stomach lining — a full stomach examination with no sedation, no endoscopic tube and no radiation. |
| Gastrin-17 (G-17) | A blood marker of stomach lining health and acid production — used alongside pepsinogen in early gastric-cancer risk screening. |
| Pepsinogen panel (PG I, PG II and ratio) | As in the Entry Panel — retained in the flagship. |
| 13C urea breath test | As in the Entry Panel — retained in the flagship. |
| Cystatin S (CST4) | A newer blood marker used in early screening and monitoring of gastrointestinal malignancies. |
| Item | What it is |
|---|---|
| 14-day continuous glucose monitoring (CGM) | A small wearable sensor continuously measures interstitial glucose for 14 days — captures post-meal spikes and overnight lows that single blood tests miss, with a data-backed report for personalized glucose management. |
| Glycated serum protein (GSP / fructosamine) | Average glucose over the preceding 2–3 weeks — complements HbA1c (2–3 months) during the monitoring period. |
| C-peptide | As in the Entry Panel — retained in the flagship. |
| Adiponectin | As in the Entry Panel — retained in the flagship. |
| HbA1c and fasting glucose | As in the Entry Panel — retained in the flagship. |
| Item | What it is |
|---|---|
| Myeloperoxidase (MPO) | An enzyme marker of vascular inflammation and plaque instability, used in cardiovascular risk assessment. |
| Lipoprotein-associated phospholipase A2 (Lp-PLA2) | An enzyme marker of atherosclerotic plaque inflammation — used alongside cholesterol measures in cardiovascular risk stratification. |
| Apolipoprotein A-I (apoA-I) | The principal protein carrier of HDL cholesterol — used in refined lipid risk assessment. |
| Homocysteine, hs-CRP, lipid panel | As in the Entry Panel — retained in the flagship. |
| Arterial stiffness measurement (PWV / ABI) | Pulse-wave velocity and ankle-brachial index — non-invasive measures of arterial wall stiffness and lower-limb circulation, used in early atherosclerosis assessment. |
| Echocardiogram, carotid ultrasound | As in the Entry Panel — retained in the flagship. |
| Item | What it is |
|---|---|
| Early kidney injury panel (7 items) | Urine microalbumin, urine creatinine, albumin/creatinine ratio (ACR), alpha-1 microglobulin, transferrin, beta-2 microglobulin and retinol-binding protein — detects the earliest glomerular and tubular kidney damage, before routine creatinine changes. |
| Liver fibrosis panel (4 items) | Hyaluronic acid, laminin, type IV collagen and procollagen III N-terminal peptide — blood markers used in the assessment of liver fibrosis. |
| Quantitative HCV RNA | Direct detection and quantification of hepatitis C virus genetic material — confirms current infection status beyond antibody screening. |
| Liver and kidney function panels | As in the Entry Panel — retained in the flagship. |
| Item | What it is |
|---|---|
| Body composition analysis | Bioelectrical-impedance measurement of body fat, muscle mass and body water — used in nutritional and metabolic assessment. |
| Trace elements panel (5 items) | Blood iron, zinc, copper, magnesium and calcium. |
| EBV DNA (quantitative) | Direct measurement of Epstein-Barr virus DNA — complements the EBV antibody test in nasopharyngeal carcinoma screening. |
| Thyroid ultrasound, abdominal ultrasound, urinary tract ultrasound | As in the Entry Panel — retained in the flagship. |
| Transvaginal pelvic ultrasound (women) | Transvaginal imaging of the uterus and ovaries — a closer view than the transabdominal approach; performed only with consent. |
| The same service items as the Entry Panel: single fasting venous blood draw, printed report with final physician review, and breakfast. CGM sensor application and the brain-package assessments are scheduled within the same visit where possible; the 14-day CGM report is issued after the monitoring window completes. |
For pricing, the $300 coordination fee and how the day runs, see the main screening page.
Tell us your dates and which panel you prefer — we will confirm the appointment window, the written quote and what to prepare before you fly.